| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-123 | |
| Phytochemical name or plant extracts | Centaurea aegyptiaca extract | |
| PMID | 28480370 | |
| Literature evidence | CONCLUSION: This study provides a better understanding of the chemistry of C. aegyptiaca that announces itself as a promising cytotoxic agent. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Methanolic extract | |
| Source of phytochemicals or plant Extracts | Centaurea aegyptiaca | |
| Geographical availability | Egypt, Oman, Palestine, Saudi Arabia, Sinai, Sudan | |
| Plant parts | Aerial parts | |
| Other cancers | Breast cancer, Liver cancer, Colon cancer, Cervical cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 30.9 μg/mL against MCF-7 | |
| Potency | This study provides a better understanding of the chemistry of C. aegyptiaca that announces itself as a promising cytotoxic agent. | |
| Cell line/ mice model | Hep-G2, MCF-7, HCT-116, HELA | |
| Additional information | Centaurea aegyptiaca demonstrated outstanding results against Hep-G2, MCF-7, HCT-116 and HELA cell lines with IC50 of 12.1, 30.9, 11.7 and 19.5 μg/mL respectively compared and doxorubicin as a reference drug. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:189803-1 | |
| Safety | NA |